Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating).[1] It is an anticholinergic and is applied to the skin.[1]
 | |
| Clinical data | |
|---|---|
| Trade names | Ecclock, Sofdra |
| Other names | BBI-4000, BBI 4000 |
| License data | |
| Routes of administration | Topical |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H32BrNO5 |
| Molar mass | 470.404 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It was approved in Japan in 2020, for the treatment of primary axillary hyperhidrosis.[2][3][4] It was approved for medical use in the United States in June 2024.[1][5]
Medical uses
Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.[1]
Mechanism of action
Sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands.[4] It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide,[6][7] meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.
Society and culture
Brand names
Sofpironium bromide is the international nonproprietary name.[8]
It is marketed as Ecclock in Japan and as Sofdra in the US.
References
External links
- "Sofpironium Bromide (Code C152384)". NCI Thesaurus.
- Clinical trial number NCT03836287 for "Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) (CardiganI)" at ClinicalTrials.gov
- Clinical trial number NCT03948646 for "Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) (CARDIGANII)" at ClinicalTrials.gov
